Oral presentations of the 6 best abstracts

**Location:** Auditorium
**Chairs:** A. Necchi, Milan (IT)  
M. Wirth, Dresden (DE)

**Saturday, 26 November**  
**11:15 - 11:55**

01 RESIRT: A phase 1 study of Selective Internal Radiation Therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres in patients with primary Renal Cell Carcinoma (RCC)

- By: De Souza P., Aslan P., Clark W., Vass J., Cade D., De Silva S.
- **Institutes:** Western Sydney University School of Medicine, Dept. of Medical Oncology, Sydney, Australia, Westmead Hospital, Dept. of Urology, Sydney, Australia, Waratah Private Hospital, The Urology Practice, Sydney, Australia, St George Private Hospital, Dept. of Radiology, Sydney, Australia, Royal North Shore Hospital, Dept. of Urology, Sydney, Australia, Sirtex Medical Limited, Medical Affairs, Sydney, Australia, Sutherland Hospital, Dept. of Radiology, Sydney, Australia

02 An interim analysis of the FUTURE trial; A RCT on target prostate biopsy based on MR imaging. Comparison of targeted and systematic biopsy outcomes

- **Institutes:** St. Antonius Ziekenhuis, Dept. of Urology, Nieuwegein, The Netherlands, Canisius Wilhelmina Ziekenhuis, Dept. of Urology, Nijmegen, The Netherlands, Universitair Medisch Centrum Utrecht, Dept. of Urology, Utrecht, The Netherlands, St. Antonius Ziekenhuis, Dept. of Pathology, Nieuwegein, The Netherlands, Canisius Wilhelmina Ziekenhuis, Dept. of Pathology, Nijmegen, The Netherlands, Radboud University Medical Centre, Dept. of Pathology, Nijmegen, The Netherlands

03 Circulating tumor (ct)-DNA profiling for potentially actionable targets in prostate cancer

- By: Sonpavde G., Nagy R., Lanman R., Talasaz A.A., Lilly M.
- **Institutes:** University of Alabama at Birmingham, Dept. of Medicine, Section of Medical Oncology, Birmingham, United States of America, Guardant Health, Inc, Dept. of Oncology, Redwood City, United States of America, Medical University of South Carolina, Dept. of Medicine, Section of Oncology, Charleston, United States of America

04 Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)

- By: Powles T., Motzer R.J., Escudier B., Scheffold C., Clary D.O., Choueiri T.K.
- **Institutes:** Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, Experimental Cancer Medicine, London, United Kingdom, Memorial Sloan Kettering Cancer Center, Medical Oncology, New York, United States of America, Institut Gustave Roussy, Renal Cancer, Villejuif, France, Tom Baker Cancer Center, Medical Oncology, Calgary, Canada, Exelixis, Inc., Clinical Development, South San Francisco, United States of America, Exelixis, Inc., Medical Affairs, South San Francisco, United States of America, Dana–Farber Cancer Institute, Lank Center For Genitourinary Oncology, Boston, United States of America

05 Exome-wide association study and risk assessment for genetic susceptibility using genetic risk score to prostate cancer in Korean population

- **Institutes:** Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea

06 Influence of cribriform/intraductal growth and percentage Gleason grade 4 on clinical outcome of
men with biopsy Gleason score 3+4=7 prostate cancer
By: Kweldam C.¹, Kummerlin I.¹, Nieboer D.², Verhoef E.¹, Steyerberg E.², Incrocci L.³, Bangma C.⁴, Van Der Kwast T.⁵, Roobol M.⁴, Van Leenders G.¹
Institutes: ¹Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Radiotherapy, Rotterdam, The Netherlands, ⁴Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ⁵University Health Network, Laboratory Medicine Program, Toronto, Canada